Previous reports attempting to evaluate the clinical efficacy of intravesical bacillus Calmette-Guérin (BCG) therapy in patients taking fibrin clot inhibitors (FCI) have yielded conflicting results and are primarily based on patient cohorts treated with only induction BCG.